Molecularly, SSAs are characterized by specific genetic alterations. Common mutations include those in the BRAF gene, and to a lesser extent, KRAS mutations. These mutations lead to the activation of the MAPK signaling pathway, contributing to the neoplastic transformation. Additionally, CpG island methylator phenotype (CIMP) is frequently observed in SSAs, leading to the silencing of tumor suppressor genes.
